{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-030814","form_type":"8-K","ticker":"BDSX","cik":"0001439725","company_name":"BIODESIX INC","filed_at":"2025-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.637478+00:00","generated_at":"2026-05-25T17:21:57.877048+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Biodesix FY2024 revenue $71.3M (+45% YoY); guides FY2025 $92-95M","bullets":["FY2024 total revenue $71.3M, up 45% YoY; gross margin 78%, up 5 pts from FY2023.","Lung Diagnostic testing revenue $64.7M (+43% YoY); Biopharma Services $6.6M (+70% YoY).","Net loss $42.9M improved 18%; adjusted EBITDA loss $22.1M improved 32% vs FY2023.","Cash $26.2M at Dec 31, 2024; post-quarter amended term loan to extend $10M Tranche C availability.","FY2025 total revenue guidance $92-95M, representing 29-33% growth over FY2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-030814","json":"https://secwatch.observer/filing/0000950170-25-030814.json","markdown":"https://secwatch.observer/filing/0000950170-25-030814.md","text":"https://secwatch.observer/filing/0000950170-25-030814.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1439725/000095017025030814/0000950170-25-030814-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1439725/000095017025030814/bdsx-20250303.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T17:21:57.877048+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}